The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Momelotinib and Fedratinib in Myelofibrosis: Beyond Ruxolitinib

Second-generation JAK inhibitors for cytopenic and relapsed disease

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Momelotinib and Fedratinib in Myelofibrosis: Beyond Ruxolitinib?

Myelofibrosis is a myeloproliferative neoplasm with bone marrow fibrosis, splenomegaly, and constitutional symptoms.

Ruxolitinib was the first approved JAK inhibitor; subsequent agents address its limitations.

Fedratinib is a selective JAK2 inhibitor approved by FDA in 2019 for intermediate-2 or high-risk primary or secondary myelofibrosis.

Momelotinib is a JAK1/JAK2/ACVR1 inhibitor approved in 2023 with anemia benefits due to ACVR1-mediated hepcidin reduction.

Pacritinib is a third agent for severely thrombocytopenic patients (platelets less than 50000).

Symptoms

Constitutional symptoms: fatigue, night sweats, weight loss, fever.
Splenomegaly causing early satiety, abdominal pain, weight loss.
Anemia from bone marrow fibrosis and ineffective hematopoiesis.
Bone pain from medullary fibrosis and extramedullary hematopoiesis.
Thrombosis or bleeding from abnormal hemostasis.

Risk Factors

Higher DIPSS-Plus risk score predicts shorter survival.
Severe anemia (transfusion dependence) makes momelotinib particularly attractive.
Thrombocytopenia limits ruxolitinib dosing; pacritinib alternative.
Prior ruxolitinib intolerance or resistance prompts fedratinib consideration.
Coexisting comorbidities limiting allogeneic transplant eligibility.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Worsening symptoms despite ruxolitinib at maximum tolerated dose.
  • New-onset anemia or transfusion need during therapy.
  • Severe weight loss, fevers, or progressive splenomegaly.
  • Cytopenias preventing dose continuation of current therapy.
  • Considering allogeneic transplant evaluation in high-risk disease.

Treatment Methods

01
Fedratinib 400 mg orally daily for ruxolitinib-resistant or intolerant patients.
02
Momelotinib 200 mg orally daily for anemic patients with myelofibrosis.
03
Boxed warning for fedratinib: encephalopathy including Wernicke; thiamine supplementation required.
04
Symptom and spleen response monitoring with TSS-MFSAF questionnaires and palpation/imaging.
05
Allogeneic stem cell transplantation remains only curative option; consider in eligible patients.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.